Latest

neuropharmacology

Featured Neuroscience Open Neuroscience Articles

·July 15, 2024·6 min read

OpenScope Project Unveils Brain’s Secrets

The OpenScope program is investigating neural activity through four new projects, exploring topics like psilocybin's effects, motion perception, visual texture recognition, and subtle changes in appearance. By using advanced imaging techniques in mice, researchers aim to understand how the brain processes these complex functions.

Featured Neurology Neuroscience

·July 15, 2024·5 min read

Anesthesia Induces Unconsciousness by Destabilizing Brain Activity

Neuroscientists have discovered that the anesthesia drug propofol causes unconsciousness by disrupting the brain's balance between stability and excitability. The drug leads to increasingly unstable brain activity, preventing the brain from maintaining normal consciousness.

Featured Neurology Neuroscience

·July 12, 2024·5 min read

Ozempic Reduces Dementia Risk, Curbs Nicotine Cravings

A new study finds that semaglutide, known as Ozempic/Wegovy, does not negatively impact brain health and may reduce cognitive problems and nicotine dependence. The analysis, using over 100 million patient records, revealed no increased risk of neurological or psychiatric conditions compared to other antidiabetic medications. These findings suggest semaglutide's benefits may extend beyond diabetes management. Further research is needed to confirm these potential benefits.

Featured Neuroscience Visual Neuroscience

·July 3, 2024·7 min read

Ozempic Linked to Increased Risk of Blinding Eye Condition

A new study reveals that patients prescribed semaglutide (Ozempic or Wegovy) for diabetes or weight loss have a higher risk of developing NAION, a potentially blinding eye condition. Diabetic patients on semaglutide were over four times more likely to be diagnosed with NAION, while overweight patients were over seven times more likely. The findings suggest the need for careful discussions between patients and doctors about this risk. NAION remains a rare but serious condition with no effective treatments.

Featured Neuroscience

·June 30, 2024·5 min read

Sleep-Deprived Memories Restored by Common Medications

Researchers have found that sleep deprivation can hide, rather than erase, memories in mice, and that these memories can be restored using existing drugs. The study demonstrated that roflumilast, an asthma medication, could recover social memories, while vardenafil, an erectile dysfunction drug, restored spatial memories.

Featured Neuroscience

·June 27, 2024·3 min read

Ozempic Boost Fullness Pre-Meal via Hypothalamus

A new study shows GLP-1 receptor agonists increase pre-meal fullness by activating neurons in the dorsomedial hypothalamus. This mechanism helps prevent overeating, offering insights into obesity treatment. The research highlights how GLP-1 impacts food perception and hypothalamic responses to food cues, enhancing satiation before food intake.

Autism Featured Neuroscience

·June 25, 2024·4 min read

CBD and Metformin Show Promise for Autism Disorders

Cannabidiol (CBD) and metformin can alleviate behavioral difficulties in mouse models of Fragile X and Phelan-McDermid syndromes. Both conditions, linked to autism spectrum disorder, saw improvements in speech, social interactions, and repetitive behaviors. This promising study paves the way for potential new treatments with minimal side effects. Ongoing clinical trials aim to confirm these findings in humans.

This shows an older man and a brain scan.

Featured Neurology Neuroscience

·June 21, 2024·4 min read

Ozempic May Reduce Alzheimer’s Risk

GLP-1 agonists like Ozempic reduce the risk of dementia in type 2 diabetes patients. The research followed over 88,000 individuals for up to ten years, showing a 30% lower risk compared to sulfonylureas and a 23% lower risk compared to DPP-4 inhibitors. These findings can guide doctors in selecting medications for older diabetes patients. However, further randomized trials are needed to confirm these results.

Featured Neurology Neuroscience

·June 21, 2024·8 min read

Synthetic Peptide Reverses Alzheimer’s Symptoms

Researchers reversed Alzheimer's symptoms in mice using a synthetic peptide, PHDP5, that targets brain function. The study shows that PHDP5 can cross the blood-brain barrier and restore memory by improving synaptic function. The treatment could delay cognitive decline if administered early. This breakthrough paves the way for new Alzheimer's therapies focusing on brain structure and function.

Brain Cancer Featured Neurology Neuroscience

·June 17, 2024·5 min read

Cancer Drug May Halt Parkinson’s Spread

Researchers discovered a novel therapeutic target for Parkinson's disease, the Aplp1 protein, which facilitates the spread of harmful alpha-synuclein proteins in the brain. Notably, an FDA-approved cancer drug targeting Lag3, a protein that interacts with Aplp1, has shown promise in blocking this spread in mouse models.

This shows the pill and a model of the intestines.

Featured Neuroscience

·June 14, 2024·4 min read

AI-Powered Pills Track Gut Health in Real Time

Scientists have created an AI-powered system to track ingestible devices that monitor disease markers in the gut. This non-invasive technology could help individuals monitor their GI tract health at home. The system uses a wearable coil and AI to precisely locate the device and measure gas concentrations. Researchers aim to refine the device for future human trials.

Featured Neurology Neuroscience

·June 10, 2024·2 min read

FDA Panel Backs Donanemab: New Hope for Early Alzheimer’s Treatment

Eli Lilly’s Alzheimer’s drug, Donanemab, has been recommended for FDA approval by an independent panel. The drug has shown promise in slowing early-stage Alzheimer’s, despite risks like brain swelling. This recommendation follows a prior FDA rejection due to insufficient data. If approved, Donanemab could revolutionize Alzheimer's treatment, offering new hope for patients and their families.